265 related articles for article (PubMed ID: 28596919)
1. Rho-Kinase/ROCK as a Potential Drug Target for Vitreoretinal Diseases.
Yamaguchi M; Nakao S; Arima M; Wada I; Kaizu Y; Hao F; Yoshida S; Sonoda KH
J Ophthalmol; 2017; 2017():8543592. PubMed ID: 28596919
[TBL] [Abstract][Full Text] [Related]
2. [Molecular mechanisms of preretinal membrane contraction in proliferative vitreoretinal diseases and ROCK as a therapeutic target].
Kita T
Nippon Ganka Gakkai Zasshi; 2010 Nov; 114(11):927-34. PubMed ID: 21141072
[TBL] [Abstract][Full Text] [Related]
3. Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target.
Kita T; Hata Y; Arita R; Kawahara S; Miura M; Nakao S; Mochizuki Y; Enaida H; Goto Y; Shimokawa H; Hafezi-Moghadam A; Ishibashi T
Proc Natl Acad Sci U S A; 2008 Nov; 105(45):17504-9. PubMed ID: 18952846
[TBL] [Abstract][Full Text] [Related]
4. Rho-kinase (ROCK) Inhibitors - A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility.
Abbhi V; Piplani P
Curr Med Chem; 2020; 27(14):2222-2256. PubMed ID: 30378487
[TBL] [Abstract][Full Text] [Related]
5. Rho kinase inhibitors: potential treatments for diabetes and diabetic complications.
Zhou H; Li YJ
Curr Pharm Des; 2012; 18(20):2964-73. PubMed ID: 22571664
[TBL] [Abstract][Full Text] [Related]
6. 2015 ATVB Plenary Lecture: translational research on rho-kinase in cardiovascular medicine.
Shimokawa H; Satoh K
Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1756-69. PubMed ID: 26069233
[TBL] [Abstract][Full Text] [Related]
7. Rho kinase inhibitors-a review on the physiology and clinical use in Ophthalmology.
Moura-Coelho N; Tavares Ferreira J; Bruxelas CP; Dutra-Medeiros M; Cunha JP; Pinto Proença R
Graefes Arch Clin Exp Ophthalmol; 2019 Jun; 257(6):1101-1117. PubMed ID: 30843105
[TBL] [Abstract][Full Text] [Related]
8. Rho-Associated Coiled-Coil Kinase (ROCK) in Molecular Regulation of Angiogenesis.
Liu J; Wada Y; Katsura M; Tozawa H; Erwin N; Kapron CM; Bao G; Liu J
Theranostics; 2018; 8(21):6053-6069. PubMed ID: 30613282
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic effects of Rho-ROCK inhibitors on CNS disorders.
Kubo T; Yamaguchi A; Iwata N; Yamashita T
Ther Clin Risk Manag; 2008 Jun; 4(3):605-15. PubMed ID: 18827856
[TBL] [Abstract][Full Text] [Related]
10. Rho Kinase (ROCK) Inhibitors and Their Therapeutic Potential.
Feng Y; LoGrasso PV; Defert O; Li R
J Med Chem; 2016 Mar; 59(6):2269-300. PubMed ID: 26486225
[TBL] [Abstract][Full Text] [Related]
11. Rho-kinase inhibitors offer a new approach in the treatment of glaucoma.
Challa P; Arnold JJ
Expert Opin Investig Drugs; 2014 Jan; 23(1):81-95. PubMed ID: 24094075
[TBL] [Abstract][Full Text] [Related]
12. Development of Rho-kinase inhibitors for cardiovascular medicine.
Shimokawa H; Rashid M
Trends Pharmacol Sci; 2007 Jun; 28(6):296-302. PubMed ID: 17482681
[TBL] [Abstract][Full Text] [Related]
13. Rho-kinase inhibitors in the management of glaucoma.
Berrino E; Supuran CT
Expert Opin Ther Pat; 2019 Oct; 29(10):817-827. PubMed ID: 31573364
[No Abstract] [Full Text] [Related]
14. AMA0428, A Potent Rock Inhibitor, Attenuates Early and Late Experimental Diabetic Retinopathy.
Hollanders K; Hove IV; Sergeys J; Bergen TV; Lefevere E; Kindt N; Castermans K; Vandewalle E; van Pelt J; Moons L; Stalmans I
Curr Eye Res; 2017 Feb; 42(2):260-272. PubMed ID: 27399806
[TBL] [Abstract][Full Text] [Related]
15. Use of Rho kinase Inhibitors in Ophthalmology: A Review of the Literature.
Moshirfar M; Parker L; Birdsong OC; Ronquillo YC; Hofstedt D; Shah TJ; Gomez AT; Hoopes PCS
Med Hypothesis Discov Innov Ophthalmol; 2018; 7(3):101-111. PubMed ID: 30386798
[TBL] [Abstract][Full Text] [Related]
16. Rho kinase inhibitors: a patent review (2014 - 2016).
Defert O; Boland S
Expert Opin Ther Pat; 2017 Apr; 27(4):507-515. PubMed ID: 28048944
[TBL] [Abstract][Full Text] [Related]
17. Rho and ROCK signaling in VEGF-induced microvascular endothelial hyperpermeability.
Sun H; Breslin JW; Zhu J; Yuan SY; Wu MH
Microcirculation; 2006; 13(3):237-47. PubMed ID: 16627366
[TBL] [Abstract][Full Text] [Related]
18. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.
Knipe RS; Tager AM; Liao JK
Pharmacol Rev; 2015; 67(1):103-17. PubMed ID: 25395505
[TBL] [Abstract][Full Text] [Related]
19. The effect of AMA0428, a novel and potent ROCK inhibitor, in a model of neovascular age-related macular degeneration.
Hollanders K; Van Bergen T; Kindt N; Castermans K; Leysen D; Vandewalle E; Moons L; Stalmans I
Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):1335-48. PubMed ID: 25626969
[TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor-beta2 and connective tissue growth factor in proliferative vitreoretinal diseases: possible involvement of hyalocytes and therapeutic potential of Rho kinase inhibitor.
Kita T; Hata Y; Kano K; Miura M; Nakao S; Noda Y; Shimokawa H; Ishibashi T
Diabetes; 2007 Jan; 56(1):231-8. PubMed ID: 17192487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
